Gamida Cell (GMDA) Pursuing Strategic Alternatives

Gamida Cell Ltd. (Nasdaq: GMDA), a cell therapy pioneer working to turn cells into powerful therapeutics, today announced it is actively pursuing strategic alternatives in order to maximize value for all stakeholders, focusing on an asset sale, merger or other strategic transaction. However, there can be no assurance that the company’s strategic alternatives process will result in any such transaction.

While pursuing strategic alternatives, the company continues to put its focus and resources behind the commercialization of Omisirge® (omidubicel-onlv), the first and only FDA-approved nicotinamide modified cell therapy donor source for allogeneic stem cell transplant.

Moelis & Company LLC is the company’s financial advisor for this process.

You May Also Be Interested In

• Air Industries revises Tenax merger terms to meet NYSE American listing rules
• MSA Safety acquires Norway-based Autronica for $555 million
• Inventurus Knowledge Solutions completes TruBridge acquisition at $26.25 a share